middle.news
Opthea Halts Wet AMD Trials After Phase III Setbacks, Cuts Staff by 65%
5:17am on Monday 2nd of June, 2025 AEST
•
Healthcare
Read Story
Opthea Halts Wet AMD Trials After Phase III Setbacks, Cuts Staff by 65%
5:17am on Monday 2nd of June, 2025 AEST
Key Points
Phase III COAST and ShORE trials failed primary endpoints
Wet AMD development program discontinued immediately
65% reduction in staff to manage clinical trial wind-down
Cash reserves at US$101.4 million with net operating outflow of US$32.4 million
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Opthea (ASX:OPT)
OPEN ARTICLE